REal World MAIA UK OutcomEs
ConditionMyeloma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe Royal Wolverhampton Hospitals NHS Trust
About this trial
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Eligibility criteria
Qualifiers
Age ≥18 years
Diagnosis of NDMM
Not eligible for autologous stem cell transplant at diagnosis
Received frontline DRd treatment following NICE approval (post-September 2023)
Disqualifiers
Participation in an interventional clinical trial for first-line therapy
Insufficient treatment or follow-up data for analysis
DRd used in relapsed/refractory setting rather than newly diagnosed disease
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
The Royal Wolverhampton Hospitals NHS Trust
Lead sponsor
Johnson & Johnson
Collaborator
Source ClinicalTrials.gov